Please use one of the following formats to cite this article in your essay, paper or report: APA. Kunkalikar, Bhavana. (2023, May 16). The safety and immunogenicity of a fourth dose of NVX-CoV2373.

As part of an ongoing phase 2, randomized, placebo-controlled clinical trial of NVX-CoV2373 that is being conducted in Australia and the United States (ClinicalTrials.gov number, NCT04368988), two ...

Research reports the results of a phase 3 clinical trial evaluating the safety, immunogenicity, and efficacy of the NVX-CoV2373 vaccine in adolescents aged 12 to 17 years. The study found that the ...

SK bioscience secured long-term license to supply NVX-CoV2373 for the Korean market. Additionally, SK bioscience has acquired non-exclusive rights to sell doses of Novavax' vaccine to the ...